| Name | Title | Contact Details |
|---|
MMS is an award-winning, global clinical research organization (CRO) that supports leading pharmaceutical and biotech companies as well as many smaller enterprises across our spectrum of services. Having completed more than 50 submissions for drug approval over the last 5 years, we remain a top choice for sponsors who are looking for innovation and demand high quality from their CRO partners. Senior leadership at MMS has more than two decades of hands-on drug development experience which helps support program-level strategy and execution of projects across multiple therapeutic areas. Continual staff training, innovative recruitment and motivating career opportunities help MMS retain the best talent and develop a strong, client-focused workforce across all global locations. Our mission is to deliver high-quality services, rooted in good science and decades of regulatory experience, that will assist our clients in developing and marketing life-changing therapies, thereby positively affecting patients` lives worldwide.
PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.
Mary Crowley Medical Research is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Syntiron is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced Clinical Services is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.